Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on developing innovative, reliable and clinically valuable products in the field of precision oncology and early detection. Its business consists of 1) therapy selection testing for cancer patients, 2) biomarker and companion diagnostic cooperation of global antineoplastic companies, and 3) multi-cancer early detection based on liquid biopsy.
In July 2018, Burning Rock has received the first approval for a tumor NGS kit by the National Medical Products Administration, which is a significant milestone in the field of in vitro diagnosis in China. The company’s lab has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory(GDCCL), and has received many international authoritative certificates such as CLIA, CAP, ISO15189, etc. The company is devoted to developing innovative and reliable testing products and advancing oncology precision medicine solutions.